Cancer vaccine

BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines

Retrieved on: 
Wednesday, February 10, 2021
Cancer, Medical specialties, Clinical medicine, Papillomavirus, Infectious causes of cancer, Vaccination, Vaccines, Gynaecological cancer, HPV vaccine, Vaccine, Human papillomavirus infection, Cancer vaccine

BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."

Key Points: 
  • BioVaxys President and Chief Operating Officer Ken Kovansaid "This co-development gives BioVaxys access to Procare Health's clinical development and regulatory expertise in the EU, and to its marketing & sales presence in Europe."
  • The collaboration with BioVaxys will help Procare Health fuel its product offerings in the gynecological oncology field.Yann Gaslain, CEO of Procare Health stated, "We are thrilled to start working the collaboration with BioVaxys as it brings a new hope in the field of gynecological cancer.
  • BioVaxys and Procare Health will split costs for feasibility, proof-of-concept, and preclinical development for a HPV viral vaccine, as well as a cervical cancer vaccine based on the BioVaxys cancer vaccine platform.
  • is a British Columbia-registered, early stage biotechnology company that is developing viral and oncology vaccine platforms, as well as immuno-diagnostics.

Worldwide Cancer Biological Toxins Drug Industry to 2026 - Featuring Angimmune, Astrazeneca and Sanofi Among Others

Retrieved on: 
Friday, February 5, 2021
Moxetumomab pasudotox, Cancer vaccine, Cancer, Treatment of cancer, Drugs, Health

DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 5, 2021 /PRNewswire/ -- The "Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
  • Global Cancer Biological Toxins Drug Market Opportunity, Drug Sales & Clinical Trials Insight 2026 Report Highlights:
    Cancer Biological Toxins Clinical Trials: >70 Drugs in Pipeline
    Global Cancer Biological Toxins Expected Market Opportunity: > US$ 200 Million
    Cancer Biological Toxins Clinical Trial Insight by Phase, Status, Cancer & Country
    Marketed Cancer Biological Toxin Clinical Insight: Moxetumomab Pasudotox (Lumoxiti)
    While hundreds of other cancer therapies are failing to stake their applications in treating cancer patients, cancer biological toxin therapy is caught in the middle to get recognized as an offering that is unimaginable.
  • Immune Checkpoint Inhibitor Therapy
    4.1.2 Cancer Biological Toxin Therapy Vs. Immunotherapy Monoclonal Antibodies
    4.1.3 Cancer Biological Toxins Therapy Market Vs. Cancer Vaccine Market
    4.2.1 Cancer Biological Toxin Therapy Market Vs.
  • Radiation Therapy for Cancer Treatment
    4.2.3 Cancer Biological Toxin Therapy Vs. Surgical Procedure for Cancer Treatment

Ultimovacs Announces NIPU Trial Design Poster Presented at World Conference of Lung Cancer Singapore 2020

Retrieved on: 
Thursday, January 28, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical trials, Branches of biology, DNA replication, Ribonucleoproteins, Senescence, Telomerase, Vaccination, Cancer vaccine, Tumor microenvironment, Biology, Clinical medicine, UV1, Ultimovacs

Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced that the lead investigator of the Companys NIPU Phase II clinical trial, slaug Helland from Oslo University Hospital, has presented a poster with an overview of the NIPU trial at the 2020 World Conference on Lung Cancer in Singapore.

Key Points: 
  • Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced that the lead investigator of the Companys NIPU Phase II clinical trial, slaug Helland from Oslo University Hospital, has presented a poster with an overview of the NIPU trial at the 2020 World Conference on Lung Cancer in Singapore.
  • For more information on the NIPU trial and the poster that was presented today, please refer to Ultimovacs corporate website.
  • UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
  • Ultimovacs UV1 universal cancer vaccine candidate leverages the high prevalence of the human telomerase (hTERT) to be effective across the dynamic stages of the tumors growth and its microenvironment.

BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

Retrieved on: 
Monday, January 25, 2021
Vaccination, Medical specialties, Medicine, Medical research, Health sciences, Vaccine, Virology, Cancer vaccine, Cancer, Tumor antigen vaccine

The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.

Key Points: 
  • The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.
  • In Phase I and Phase II clinical studies previously conducted by BioVaxys, co-founder and Chief Medical Officer, David Berd MD, using an earlier generation of the BioVaxys cancer vaccine on nearly 500 patients with melanoma or ovarian cancer, the haptenized cell platform showed significant clinical promise.
  • A way to achieve this is by the use of a hapten, which is the foundation for the BioVaxys' haptenized protein vaccine platform."
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

Retrieved on: 
Monday, January 25, 2021
Vaccination, Medical specialties, Medicine, Medical research, Health sciences, Vaccine, Virology, Cancer vaccine, Cancer, Tumor antigen vaccine

The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.

Key Points: 
  • The case-to-fatality ratio is nearly three times that of breast cancer and makes ovarian cancer the deadliest gynecologic malignancy in developed countries.
  • In Phase I and Phase II clinical studies previously conducted by BioVaxys, co-founder and Chief Medical Officer, David Berd MD, using an earlier generation of the BioVaxys cancer vaccine on nearly 500 patients with melanoma or ovarian cancer, the haptenized cell platform showed significant clinical promise.
  • A way to achieve this is by the use of a hapten, which is the foundation for the BioVaxys' haptenized protein vaccine platform."
  • BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies.

NEUVOGEN Announces Participation at B. Riley Virtual Oncology Investor Conference

Retrieved on: 
Wednesday, January 20, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Oncology, Cancer vaccine, Immunotherapy, Immune system, Tumor antigen, Vaccine, Tumor antigen vaccine, Active immunotherapy

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ --NEUVOGEN todayannounced that Todd Binder, Chief Executive Officer of NEUVOGEN, will participate in the B. Riley Virtual Oncology Investor Conference:

Key Points: 
  • SAN DIEGO, Jan. 20, 2021 /PRNewswire/ --NEUVOGEN todayannounced that Todd Binder, Chief Executive Officer of NEUVOGEN, will participate in the B. Riley Virtual Oncology Investor Conference:
    NEUVOGEN, Inc. is an immunoncology company focused on whole cell cancer vaccine therapies.
  • NEUVOGEN's immunotherapies have the potential to deliver the broadest ever combination of tumor antigens to prime immune response.
  • Based in San Diego, California, NEUVOGEN's goal is to bring to market a pipeline of therapeutic cancer vaccines that activate the body's immune system to eradicate solid tumors and meaningfully extend the lives of patients while limiting side effects generally associated with traditional cancer treatments.
  • To learn more, visit www.neuvogen.com

NEUVOGEN Announces Next Generation Cancer Vaccine Strategy to Transform how Solid Tumors are Treated

Retrieved on: 
Wednesday, January 20, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Immunotherapy, Virotherapy, Cancer vaccine, Cancer, Health sciences, Vaccines

SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- NEUVOGEN, an immunoncology company, announces its novel cancer vaccine strategy to transform how solid tumors are treated.

Key Points: 
  • SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- NEUVOGEN, an immunoncology company, announces its novel cancer vaccine strategy to transform how solid tumors are treated.
  • "We believe NEUVOGEN's cancer vaccines will deliver the broadest immune-priming ever achieved to transform the way solid tumors are treated.
  • NEUVOGEN is advancing discovery and development programs that will transform how solid tumors are treated by:
    "NEUVOGEN has the potential to disrupt the current immunoncology treatment paradigm by turning our technologies into a pipeline of truly novel cancer immunotherapies for various solid tumors."
  • "The NEUVOGEN whole cell platform has the ability to transform the clinical landscape of how we treat patients with solid tumors."

Expanding Cancer Immunotherapy by Exploiting Recall Immunity -- A New Co-Therapy Option for Checkpoint Inhibitors, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, January 14, 2021
Clinical medicine, Medicine, Medical specialties, Virotherapy, Oncology, Cancer immunotherapy, Immunotherapy, Cancer, Checkpoint inhibitor, Cancer vaccine, Tumor antigen vaccine

Despite the significant improvement in prognosis for some cancer patients, there are challenges in using CIs for the treatment of all cancers.

Key Points: 
  • Despite the significant improvement in prognosis for some cancer patients, there are challenges in using CIs for the treatment of all cancers.
  • They are also not as effective in tumors with low mutational burden, due to the dependence on tumor "self" antigens for immune recognition.
  • Therefore, there is a need for a solution to improve the efficacy of CIs to make them applicable to the entire cancer patient population.
  • For more information, or to register for this event, visit Expanding Cancer Immunotherapy by Exploiting Recall Immunity A New Co-Therapy Option for Checkpoint Inhibitors.

Global Opportunity Analysis and Industry Forecast in the Cancer Vaccines Market to 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 4, 2021
Pharmaceutical, Health, Oncology, Medical specialties, Vaccination, Branches of biology, Medicine, Vaccines, Virology, Cancer vaccines, Vaccine, Gene delivery, Viral vector, Cancer vaccine, Vaccine therapy

The "Cancer Vaccines Market by Technology Cancer Vaccines, Type, Indication, End User - Global Opportunity Analysis and Industry Forecast, 2019 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer Vaccines Market by Technology Cancer Vaccines, Type, Indication, End User - Global Opportunity Analysis and Industry Forecast, 2019 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Increasing administration of prophylactic cancer vaccines and rising investments for the development of new cancer vaccines are expected to fuel the cancer vaccines market growth.
  • Moreover, factors such as emphasis on early diagnosis of cancer, introduction & approval of cancer vaccines and technological developments are expected to boost the demand for cancer vaccines market growth.
  • On the basis of technology, the market is segregated into dendritic cells cancer vaccines, recombinant cancer vaccine, antigen cancer vaccine and viral vector & DNA cancer vaccines.

Europe Cancer Vaccines Markets, 2019-2020 & 2027 - Dendritic Cells Cancer Vaccines Segment to Grow at Fastest Rate

Retrieved on: 
Thursday, December 10, 2020
Vaccination, Medical specialties, Medicine, Clinical medicine, Vaccines, Vaccine, Virology, Cancer vaccines, Cancer vaccine, Viral vector, Vaccine therapy, Therapeutic vaccines

Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines.

Key Points: 
  • Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines.
  • The in recombinant cancer vaccines segment held the largest share of the market in 2019.
  • Moreover, recombinant cancer vaccines is estimated grow at the highest CAGR in the market during the forecast period.
  • Market growth in Europe Cancer Vaccines is mainly due to factors such as increasing prevalence of cancer and rising government initiatives to prevent cancer.